Senior management reorganization at DOV Pharma

9 July 2006

USA-based DOV Pharmaceuticals says that Leslie Hudson has resigned as president, chief executive and board member, and that his posts as president and board member have been taken up by current chief financial officer Barbara Duncan. Also, the firm's

chief scientific officer, Phil Skolnick, has been named executive vice president and CSO, current chairman Arnold Lippa is now executive chairman of the board. The moves are aimed at maximizing DOV's existing pipeline and to "explore and pursue" its "most attractive financing opportunities."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight